Stryker Co. (NYSE:SYK) Shares Sold by Northstar Asset Management Inc.

Northstar Asset Management Inc. lessened its holdings in Stryker Co. (NYSE:SYK) by 0.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,774 shares of the medical technology company’s stock after selling 122 shares during the quarter. Stryker accounts for approximately 4.6% of Northstar Asset Management Inc.’s investment portfolio, making the stock its 4th biggest holding. Northstar Asset Management Inc.’s holdings in Stryker were worth $18,704,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SYK. Norden Group LLC acquired a new stake in shares of Stryker in the 1st quarter valued at approximately $280,000. Central Pacific Bank Trust Division acquired a new stake in Stryker in the first quarter valued at $39,000. Cohen Capital Management Inc. grew its position in shares of Stryker by 0.3% in the 1st quarter. Cohen Capital Management Inc. now owns 85,108 shares of the medical technology company’s stock valued at $30,458,000 after acquiring an additional 261 shares during the period. TFG Advisers LLC increased its stake in shares of Stryker by 0.8% during the 1st quarter. TFG Advisers LLC now owns 13,614 shares of the medical technology company’s stock worth $4,872,000 after purchasing an additional 102 shares during the last quarter. Finally, Manchester Capital Management LLC raised its holdings in shares of Stryker by 1.4% in the 1st quarter. Manchester Capital Management LLC now owns 2,474 shares of the medical technology company’s stock valued at $885,000 after purchasing an additional 34 shares during the period. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price target on Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Wolfe Research assumed coverage on Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. UBS Group lifted their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Royal Bank of Canada increased their price objective on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley increased their price target on shares of Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Stock Performance

Shares of Stryker stock opened at $369.86 on Wednesday. The business has a 50-day moving average price of $360.66 and a two-hundred day moving average price of $344.95. Stryker Co. has a 1-year low of $266.93 and a 1-year high of $374.63. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $141.00 billion, a P/E ratio of 39.64, a PEG ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at $3,715,540. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,068 shares of company stock worth $3,693,972. Corporate insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.